Biolinerx Stock Buy Hold or Sell Recommendation
| BLRX Stock | USD 0.27 0.01 3.57% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding BioLineRx is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell BioLineRx given historical horizon and risk tolerance towards BioLineRx. When Macroaxis issues a 'buy' or 'sell' recommendation for BioLineRx, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out BioLineRx Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide. In addition, we conduct extensive research on individual companies such as BioLineRx and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards BioLineRx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
BioLineRx |
Execute BioLineRx Buy or Sell Advice
The BioLineRx recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on BioLineRx. Macroaxis does not own or have any residual interests in BioLineRx or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute BioLineRx's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
BioLineRx Trading Alerts and Improvement Suggestions
| BioLineRx generated a negative expected return over the last 90 days | |
| BioLineRx has high historical volatility and very poor performance | |
| BioLineRx has some characteristics of a very speculative penny stock | |
| BioLineRx has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 4.8 M. Net Loss for the year was (60.61 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| BioLineRx currently holds about 43.15 M in cash with (22.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| BioLineRx has a frail financial position based on the latest SEC disclosures | |
| Latest headline from seekingalpha.com: BioLineRx Q3 2024 Earnings Preview |
BioLineRx Returns Distribution Density
The distribution of BioLineRx's historical returns is an attempt to chart the uncertainty of BioLineRx's future price movements. The chart of the probability distribution of BioLineRx daily returns describes the distribution of returns around its average expected value. We use BioLineRx price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of BioLineRx returns is essential to provide solid investment advice for BioLineRx.
| Mean Return | -1.14 | Value At Risk | -9.8 | Potential Upside | 4.88 | Standard Deviation | 6.83 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of BioLineRx historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
BioLineRx Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as BioLineRx, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading BioLineRx back and forth among themselves.
| Shares | Two Sigma Securities, Llc | 2024-06-30 | 46.2 K | Xtx Topco Ltd | 2024-09-30 | 44.1 K | Orin Green Financial, Llc | 2024-09-30 | 43 K | Geode Capital Management, Llc | 2024-09-30 | 40 K | Rathbone Brothers Plc | 2024-06-30 | 39.8 K | Gradient Investments | 2024-09-30 | 30 K | Rhumbline Advisers | 2024-06-30 | 25.7 K | Weaver Consulting Group | 2024-06-30 | 16.9 K | Cutter & Co Brokerage, Inc. | 2024-09-30 | 16.7 K | Alyeska Investment Group, L.p. | 2024-09-30 | 866.5 K | Cvi Holdings Llc | 2024-06-30 | 815.7 K |
BioLineRx Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 1.9M | 11.5M | (3.8M) | (2.4M) | (6.3M) | (6.0M) | |
| Free Cash Flow | (22.7M) | (23.2M) | (23.7M) | (26.6M) | (22.9M) | (24.1M) | |
| Depreciation | 940K | 934K | 703K | 654K | 1.4M | 1.5M | |
| Other Non Cash Items | (72K) | 242K | 39K | (5.4M) | 21.9M | 23.0M | |
| Capital Expenditures | 10.2M | 73K | 97K | 316K | 297K | 282.2K | |
| Net Income | (25.4M) | (30.0M) | (27.1M) | (25.0M) | (60.6M) | (57.6M) | |
| End Period Cash Flow | 5.3M | 16.8M | 13.0M | 10.6M | 4.3M | 8.0M | |
| Investments | 5.3M | 16.7M | (38.1M) | 4.0M | 1.4M | 1.5M | |
| Net Borrowings | 9.2M | (1.1M) | (3.4M) | (3.6M) | (3.2M) | (3.1M) | |
| Change To Netincome | (73K) | (3.0M) | 6.6M | 3.3M | 3.8M | 4.0M |
BioLineRx Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to BioLineRx or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that BioLineRx's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a BioLineRx stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.12 | |
β | Beta against Dow Jones | -0.23 | |
σ | Overall volatility | 6.92 | |
Ir | Information ratio | -0.19 |
BioLineRx Volatility Alert
BioLineRx is displaying above-average volatility over the selected time horizon. BioLineRx is a potential penny stock. Although BioLineRx may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in BioLineRx. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on BioLineRx instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.BioLineRx Fundamentals Vs Peers
Comparing BioLineRx's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze BioLineRx's direct or indirect competition across all of the common fundamentals between BioLineRx and the related equities. This way, we can detect undervalued stocks with similar characteristics as BioLineRx or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of BioLineRx's fundamental indicators could also be used in its relative valuation, which is a method of valuing BioLineRx by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare BioLineRx to competition |
| Fundamentals | BioLineRx | Peer Average |
| Return On Equity | -1.72 | -0.31 |
| Return On Asset | -0.35 | -0.14 |
| Profit Margin | (1.77) % | (1.27) % |
| Operating Margin | (1.07) % | (5.51) % |
| Current Valuation | 25.74 M | 16.62 B |
| Shares Outstanding | 79.94 M | 571.82 M |
| Shares Owned By Insiders | 8.53 % | 10.09 % |
| Shares Owned By Institutions | 3.09 % | 39.21 % |
| Number Of Shares Shorted | 1.06 M | 4.71 M |
| Price To Earning | (3.88) X | 28.72 X |
| Price To Book | 1.59 X | 9.51 X |
| Price To Sales | 1.30 X | 11.42 X |
| Revenue | 4.8 M | 9.43 B |
| EBITDA | (57.06 M) | 3.9 B |
| Net Income | (60.61 M) | 570.98 M |
| Cash And Equivalents | 43.15 M | 2.7 B |
| Cash Per Share | 0.90 X | 5.01 X |
| Total Debt | 11.59 M | 5.32 B |
| Debt To Equity | 0.05 % | 48.70 % |
| Current Ratio | 4.58 X | 2.16 X |
| Book Value Per Share | 0.01 X | 1.93 K |
| Cash Flow From Operations | (22.61 M) | 971.22 M |
| Short Ratio | 2.39 X | 4.00 X |
| Earnings Per Share | (0.45) X | 3.12 X |
| Price To Earnings To Growth | 0.20 X | 4.89 X |
| Target Price | 9.83 | |
| Number Of Employees | 79 | 18.84 K |
| Beta | 0.87 | -0.15 |
| Market Capitalization | 22.23 M | 19.03 B |
| Total Asset | 63.92 M | 29.47 B |
| Retained Earnings | (390.61 M) | 9.33 B |
| Working Capital | 16.33 M | 1.48 B |
| Current Asset | 48.18 M | 9.34 B |
BioLineRx Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as BioLineRx . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 919852.0 | |||
| Daily Balance Of Power | (0.25) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 0.27 | |||
| Day Typical Price | 0.27 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.01) | |||
| Relative Strength Index | 46.71 |
About BioLineRx Buy or Sell Advice
When is the right time to buy or sell BioLineRx? Buying financial instruments such as BioLineRx Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having BioLineRx in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cancer Fighters Thematic Idea Now
Cancer Fighters
Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. The Cancer Fighters theme has 60 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cancer Fighters Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for BioLineRx Stock Analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.